Search

Your search keyword '"Bagot, Catherine"' showing total 10 results
Start Over Author "Bagot, Catherine" Journal blood
10 results on '"Bagot, Catherine"'

1. Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Author

Kenet, Gili, Nolan, Beatrice, Zulfikar, Bulent, Antmen, Bulent, Kampmann, Peter, Matsushita, Tadashi, You, Chur-Woo, Vilchevska, Kateryna, Bagot, Catherine N., Sharif, Azizan, Peyvandi, Flora, Young, Guy, Negrier, Claude, Chi, Jiarui, Kittner, Barbara, Sussebach, Christian, Shammas, Fadi, Mei, Baisong, Andersson, Shauna, and Kavakli, Kaan

Published
2024
Full Text
View/download PDF

3. Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)

Author

Srivastava, Alok, primary, Rangarajan, Savita, additional, Kavakli, Kaan, additional, Klamroth, Robert, additional, Kenet, Gili, additional, Khoo, Liane, additional, You, Chur-Woo, additional, Xu, Weiqun, additional, Malan, Niel, additional, Frenzel, Laurent, additional, Bagot, Catherine N., additional, Stasyshyn, Oleksandra, additional, Chang, Chia-Yau, additional, Poloskey, Stacey, additional, Andersson, Shauna, additional, Qiu, Zhiying, additional, Mei, Baisong, additional, and Pipe, Steven W., additional

Published
2021
Full Text
View/download PDF

4. A Multicentre Randomised Trial of First Line Treatment Pathways for Newly Diagnosed Immune Thrombocytopenia: Standard Steroid Treatment Versus Combined Steroid and Mycophenolate. the Flight Trial

Author

Bradbury, Charlotte A, primary, Greenwood, Rosemary, additional, Pell, Julie, additional, Breheny, Katie, additional, Kandiyali, Rebecca, additional, Ingram, Jenny, additional, Thomas, Ian, additional, Bagot, Catherine, additional, Hill, Quentin, additional, Collaborators, HaemSTAR, additional, and Cooper, Nichola, additional

Published
2020
Full Text
View/download PDF

8. The Outcome of Lymphoproliferative Disorder in Liver Transplant Recipients May Correlate with Age at Diagnosis and the Use of Chemotherapy: A Single Centre Report.

Author

Bagot, Catherine N., primary, Kulasekararaj, Austin, primary, Ramalingam, Sandeep, primary, Heaton, Nigel, primary, O’Grady, John, primary, Hadzic, Dino, primary, Portmann, Bernard, primary, Rela, Mohamed, primary, Salisbury, Jon, primary, Devereux, Steven, primary, Mufti, Ghulam J., primary, and Pagliuca, Antonio, primary

Published
2005
Full Text
View/download PDF

9. Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy

Author

Doyle, Andrew J., Stubbs, Matthew J., Dutt, Tina, Lester, Will, Thomas, Will, van Veen, Joost, Hermans, Joannes, Cranfield, Tanya, Hill, Quentin A., Clark, Amanda, Bagot, Catherine, Austin, Steven, Westwood, John-Paul, Thomas, Mari, and Scully, Marie

Abstract

Disease relapse is recognized as a risk in immune-mediated thrombotic thrombocytopenic purpura (iTTP) after treatment of the acute presenting episode. Identification of patients at risk of relapse and its patterns are yet to be clearly established. We reviewed patients with iTTP having had >3 years of follow-up over 10 years in the United Kingdom to identify patient characteristics for relapse, assess relapse rates and patterns, and response to anti-CD20 therapy in those with a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) relapses (ADAMTS13 activity of <20% without thrombocytopenia). We identified 443 patients demonstrating relapse rates of 40% at 5-year follow-up. At 10-year follow-up, no difference in relapse was observed irrespective of whether rituximab was used at acute presentation (P = .39). Black Caribbean ethnicity increased the risk of disease relapse in the British population. There was a distinct population of patients (6%) that relapsed early with subsequent frequent relapses occurring on average within 2 years (average time to relapse in subgroup, 1.7 years). Overall, nearly 60% of relapses described were ADAMTS13 relapses, with subsequent treatment reducing the risk of progression to clinical relapses. We demonstrate that iTTP diagnosed in the latter part of the study period had lower rates of clinical relapses (22.6% vs 11.1%, P = .0004) with the advent of regular monitoring and preemptive rituximab. In ADAMTS13 relapses, 96% responded to anti-CD20 therapy, achieving ADAMTS13 activity of >20%. Anti-CD20 therapy was demonstrated to be an effective long-term treatment regardless of relapse pattern and there was no loss of this treatment response after subsequent treatment episodes.

Published
2022
Full Text
View/download PDF

10. Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B withoutInhibitors (ATLAS-A/B)

Author

Srivastava, Alok, Rangarajan, Savita, Kavakli, Kaan, Klamroth, Robert, Kenet, Gili, Khoo, Liane, You, Chur-Woo, Xu, Weiqun, Malan, Niel, Frenzel, Laurent, Bagot, Catherine N., Stasyshyn, Oleksandra, Chang, Chia-Yau, Poloskey, Stacey, Andersson, Shauna, Qiu, Zhiying, Mei, Baisong, and Pipe, Steven W.

Abstract

Background

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results